CN102138966B - 藏茵陈提取物及其制备方法、药物组合物和用途 - Google Patents
藏茵陈提取物及其制备方法、药物组合物和用途 Download PDFInfo
- Publication number
- CN102138966B CN102138966B CN 201010106232 CN201010106232A CN102138966B CN 102138966 B CN102138966 B CN 102138966B CN 201010106232 CN201010106232 CN 201010106232 CN 201010106232 A CN201010106232 A CN 201010106232A CN 102138966 B CN102138966 B CN 102138966B
- Authority
- CN
- China
- Prior art keywords
- extract
- zangyinchen
- constituents
- preparation
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 120
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 238000000605 extraction Methods 0.000 title claims description 15
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 117
- 239000003814 drug Substances 0.000 claims description 58
- 239000000470 constituent Substances 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000011347 resin Substances 0.000 claims description 28
- 229920005989 resin Polymers 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000012567 medical material Substances 0.000 claims description 17
- 239000003208 petroleum Substances 0.000 claims description 16
- 208000006454 hepatitis Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- -1 oral solution Substances 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 13
- 238000001556 precipitation Methods 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000003463 adsorbent Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 241000501704 Swertia franchetiana Species 0.000 claims description 10
- 241000977602 Swertia mussotii Species 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 claims description 6
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 claims description 6
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 claims description 6
- HEYZWPRKKUGDCR-QBXMEVCASA-N Swertiamarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@]2(O)CCOC(=O)C2=CO1 HEYZWPRKKUGDCR-QBXMEVCASA-N 0.000 claims description 6
- HEYZWPRKKUGDCR-WRMJXEAJSA-N Swertiamarin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1 HEYZWPRKKUGDCR-WRMJXEAJSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000009633 chimonin Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 claims description 6
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 5
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 5
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 5
- CYNUMZCJGCZYTD-UHFFFAOYSA-N Swertianolin Natural products O1C2=C(O)C=CC(O)=C2C(=O)C=2C1=CC(OC)=CC=2OC1OC(CO)C(O)C(O)C1O CYNUMZCJGCZYTD-UHFFFAOYSA-N 0.000 claims description 5
- 229940100243 oleanolic acid Drugs 0.000 claims description 5
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- XMVBNLMKPMPWAX-DIKOWXHZSA-N swertianolin Chemical compound C=1C(OC)=CC(O)=C(C(C2=3)=O)C=1OC2=C(O)C=CC=3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XMVBNLMKPMPWAX-DIKOWXHZSA-N 0.000 claims description 5
- XMVBNLMKPMPWAX-UHFFFAOYSA-N swertianoline Natural products C=1C(OC)=CC(O)=C(C(C2=3)=O)C=1OC2=C(O)C=CC=3OC1OC(CO)C(O)C(O)C1O XMVBNLMKPMPWAX-UHFFFAOYSA-N 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims 5
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 abstract description 31
- 206010067125 Liver injury Diseases 0.000 abstract description 19
- 231100000439 acute liver injury Toxicity 0.000 abstract description 19
- 239000000126 substance Substances 0.000 abstract description 7
- 206010023129 Jaundice cholestatic Diseases 0.000 abstract description 5
- 201000005267 Obstructive Jaundice Diseases 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 description 61
- 210000000941 bile Anatomy 0.000 description 35
- 210000004185 liver Anatomy 0.000 description 33
- 238000010828 elution Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 210000003494 hepatocyte Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 230000002440 hepatic effect Effects 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 11
- 229930182470 glycoside Natural products 0.000 description 11
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 11
- 244000111489 Gardenia augusta Species 0.000 description 10
- 235000018958 Gardenia augusta Nutrition 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 230000017074 necrotic cell death Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 230000003908 liver function Effects 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241001530209 Swertia Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 244000141698 Prunus lannesiana Species 0.000 description 4
- 235000014001 Prunus serrulata Nutrition 0.000 description 4
- JDIORNFCMMYMLF-UHFFFAOYSA-N bellidifolin Chemical compound C1=CC(O)=C2C(=O)C3=C(O)C=C(OC)C=C3OC2=C1O JDIORNFCMMYMLF-UHFFFAOYSA-N 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000001989 choleretic effect Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LQEJBIQAJBRLMB-UHFFFAOYSA-N Bellidifolin Natural products OC1=CC(=CC=2OC3=C(C=CC(=C3C(C1=2)=O)OC)O)O LQEJBIQAJBRLMB-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- CNMVOPXKKWCJHT-UHFFFAOYSA-N isogentiakochianin Natural products OC1=CC(O)=C2C(=O)C3=C(O)C(OC)=CC=C3OC2=C1 CNMVOPXKKWCJHT-UHFFFAOYSA-N 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 241000501664 Gentianopsis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000220151 Saxifragaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- YKGYQYOQRGPFTO-UHFFFAOYSA-N bis(8-methylnonyl) hexanedioate Chemical compound CC(C)CCCCCCCOC(=O)CCCCC(=O)OCCCCCCCC(C)C YKGYQYOQRGPFTO-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010106232 CN102138966B (zh) | 2010-01-29 | 2010-01-29 | 藏茵陈提取物及其制备方法、药物组合物和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010106232 CN102138966B (zh) | 2010-01-29 | 2010-01-29 | 藏茵陈提取物及其制备方法、药物组合物和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102138966A CN102138966A (zh) | 2011-08-03 |
CN102138966B true CN102138966B (zh) | 2013-04-10 |
Family
ID=44406908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010106232 Active CN102138966B (zh) | 2010-01-29 | 2010-01-29 | 藏茵陈提取物及其制备方法、药物组合物和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102138966B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102696638B (zh) * | 2012-04-19 | 2013-10-16 | 云南省农业科学院生物技术与种质资源研究所 | 獐牙菜苷药物制剂及其在防治烟草花叶病毒病中的应用 |
CN103271357A (zh) * | 2013-05-31 | 2013-09-04 | 南京年吉冷冻食品有限公司 | 一种健康食品及其制备方法 |
CN103408602B (zh) * | 2013-07-22 | 2016-01-20 | 中国科学院西北高原生物研究所 | 一种从藏茵陈中分离制备四种苷类化学对照品的方法 |
CN104650024B (zh) * | 2014-01-27 | 2018-04-27 | 北京大学 | 生物类口山酮类单体化合物抗肝纤维化和肝硬化的用途 |
CN104971088A (zh) * | 2014-04-11 | 2015-10-14 | 中央民族大学 | 藏茵陈提取物及其制备方法、药物组合物和用途 |
CN104188994A (zh) * | 2014-08-22 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用獐牙菜苦苷作为治疗胆汁淤积的药物的应用 |
CN105367536A (zh) * | 2015-12-18 | 2016-03-02 | 姚天文 | 一种新的环烯醚萜类化合物及其制备方法和医药用途 |
CN105770001A (zh) * | 2016-04-27 | 2016-07-20 | 周德珍 | 用于预防胆汁淤积性黄疽并发症的颗粒剂及其制备方法 |
CN108117571B (zh) * | 2018-01-31 | 2021-03-02 | 湖南佳沐生物科技有限公司 | 一种龙胆苦苷单体的制备方法 |
CN111617132B (zh) * | 2020-06-12 | 2022-01-04 | 西藏天虹科技股份有限责任公司 | 藏茵陈提取物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101053589A (zh) * | 2007-04-30 | 2007-10-17 | 王智森 | 藏茵陈有效成分的提取方法 |
CN101396428A (zh) * | 2007-09-30 | 2009-04-01 | 中国科学院西北高原生物研究所 | 藏茵陈提取物及其制备方法、药物组合物和用途 |
-
2010
- 2010-01-29 CN CN 201010106232 patent/CN102138966B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101053589A (zh) * | 2007-04-30 | 2007-10-17 | 王智森 | 藏茵陈有效成分的提取方法 |
CN101396428A (zh) * | 2007-09-30 | 2009-04-01 | 中国科学院西北高原生物研究所 | 藏茵陈提取物及其制备方法、药物组合物和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102138966A (zh) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102138966B (zh) | 藏茵陈提取物及其制备方法、药物组合物和用途 | |
Li et al. | Acute and sub-chronic oral toxicity studies of hesperidin isolated from orange peel extract in Sprague Dawley rats | |
CN101073599B (zh) | 丹参中总丹参酮及总酚酸提取物及其制备方法 | |
CN101244129B (zh) | 拉萨大黄提取物、其制备方法及其在制备治疗心脑血管疾病制剂中的应用 | |
CN101249118A (zh) | 一种中药提取物及其医药用途 | |
CN101744978B (zh) | 预防和治疗糖尿病的药物组合物 | |
CN102078443B (zh) | 一种药物组合物及其用途和制剂 | |
CN100475228C (zh) | 一种杏香兔耳风提取物及其制备方法 | |
CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
CN102526141B (zh) | 翼首草总环烯醚萜苷提取物及其制备方法和用途 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN101757073B (zh) | 含有苍术提取物的药物组合物 | |
CN104971088A (zh) | 藏茵陈提取物及其制备方法、药物组合物和用途 | |
CN100477996C (zh) | 虎眼万年青提取物及其制备方法、药物组合物以及用途 | |
CN104324089A (zh) | 各种成分比例稳定均一的大黄总蒽醌及其组合物用于乙型病毒性肝炎的退黄治疗 | |
CN104224952A (zh) | 一种各种成分比例稳定均一的大黄总蒽醌的制备方法 | |
CN1969963A (zh) | 一种治疗肝炎的药物有效成份提取方法及其药物组合 | |
CN100431566C (zh) | 一种中药组合物及其制备方法和应用 | |
Lan et al. | Safety assessment of saponins extract in Dolichos falcatus Klein: subchronic study in Sprague-Dawley rats | |
CN102652791B (zh) | 一种具有抗肝纤维化作用的药物组合物及制备方法 | |
CN112546085A (zh) | 一种治疗痛风的接骨草提取物及其制备方法 | |
CN101670007B (zh) | 一种预防和治疗肾脏疾病的药物及其制备方法 | |
CN104116753A (zh) | 桃叶珊瑚苷在制备治疗特发性肺纤维化药物中的应用 | |
CN113384667B (zh) | 一种防治肝损伤和/或肝癌的药物组合物及其制备方法和用途 | |
CN103536637A (zh) | 鹿草降血脂提取物的制备及分离方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231016 Address after: 4th Floor, Building B1, No. 306 Huiren Road, Binhai Science and Technology Park, Binhai New Area, Tianjin, 300451 Patentee after: Heguang Traditional Chinese Medicine Technology (Tianjin) Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. |
|
TR01 | Transfer of patent right |